Bicyclic heterocycles useful as serine protease inhibitors

Details Bicyclic heterocycles useful as serine protease inhibitors Bicyclic heterocycles useful as serine protease inhibitors

2005-04-11

2008-08-26

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S470000

Reexamination Certificate

active

07417063

ABSTRACT:
The present invention provides compounds of Formula (I):or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, L1, L2, X1, X2, X3, X4, X5, R4, and W are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

REFERENCES:
patent: 4581354 (1986-04-01), Bell
patent: 4634776 (1987-01-01), Bell
patent: 4885295 (1989-12-01), Bell
patent: 4978664 (1990-12-01), Bell
patent: 5013732 (1991-05-01), Bell
patent: 5312829 (1994-05-01), Okada et al.
patent: 5604253 (1997-02-01), Lau et al.
patent: 5639780 (1997-06-01), Lau et al.
patent: 5684034 (1997-11-01), Bach et al.
patent: 5811425 (1998-09-01), Woods et al.
patent: 6069156 (2000-05-01), Oku et al.
patent: 6100238 (2000-08-01), Gyorkos et al.
patent: 6166023 (2000-12-01), Schindler et al.
patent: 6358992 (2002-03-01), Pamukcu et al.
patent: 6653304 (2003-11-01), Leftheris et al.
patent: 6858577 (2005-02-01), Zhang et al.
patent: 2003/0203909 (2003-10-01), Ushio et al.
patent: 2004/0006123 (2004-01-01), Alkan et al.
patent: 2004/0220206 (2004-11-01), Smallheer et al.
patent: 2004/0235847 (2004-11-01), Quan et al.
patent: WO 93/02050 (1993-02-01), None
patent: WO 98/08818 (1998-03-01), None
patent: WO 99/12903 (1999-03-01), None
patent: WO 99/12935 (1999-03-01), None
patent: WO 99/43654 (1999-09-01), None
patent: WO 00/35886 (2000-06-01), None
patent: WO 01/27079 (2001-04-01), None
patent: WO01058869 (2001-08-01), None
patent: WO 03/101961 (2003-12-01), None
patent: WO 2004/050637 (2004-06-01), None
patent: WO 2004/062661 (2004-07-01), None
patent: WO 2004/080971 (2004-09-01), None
patent: WO 2004/094372 (2004-11-01), None
Walsh, P.N., “Platelets and Factor XI Bypass the Contact System of Blood Coagulation”,Thromb. and Haemostasis, 82(2), pp. 234-242, 1999.
Colman, R. Contact Activation Pathway: Inflammatory, Fibrinolytic, Anticoagulant, Antiadhesive, and Antiangiogenic Activities,Hemostasis and thrombosis: basic principles and clinical practice, Lippincott Williams & .Wilkins, 2001, pp. 103-122.
Schmaier, A.H., “Contact Activation”,Thrombosis and Hemorrhage, Williams&Wilkins, 1998, Chapter 5, pp. 105-128.
Gailani, D., “Activation of Factor IX by Factor XIa”,Trends in Cardiovascular Medicine, vol. 10, No. 5, 2000, pp. 198-204.
Bouma, B.N. et al., “Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Precarboxypeptidase R, Procarboxypeptidase U)”,Thrombosis. Research, 2001, 101, pp. 329-354.
Gailani, D., “Gene Targeting in Hemostasis. Factor XI”,Frontiers in Bioscience, 2001, 6, pp. d201-d207.
Gailani, D., et al., “A murine model of factor XI deficiency”,Blood Coagulation and Fibrinolysis, 1997, vol. 8, pp. 134-144.
Minnema, M.C., et al., “Activation of Clotting Factors XI and IX in Patients with Acute Myocardial Infarction”,Arterioscler. Thromb. Vasc. Biol., 2000, 20, pp. 2489-2493.
Murakami, T., et al., “Evaluation of Factor XIa-α1—Antitrypsin in Plasma, a Contact Phase-Activated Coagulation Factor-Inhibitor Complex, in Patients With Coronary Artery Disease”,Arterioscler. Thromb. Vasc. Biol., 1995, vol. 15, No. 8, pp. 1107-1113.
Meijers, J.C.M., et al., “High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis”,N. Engl. J. Med., 2000, vol. 342, No. 10, pp. 696-701.
Komoriya et al., “Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites”,Bioorganic&Medicinal Chemistry, vol. 12, pp. 2099-2114, 2004.
Zhang et al., “A Versatile Synthesis of 3-Substituted Indolines and Indoles”,J. Org. Chem., vol. 61, pp. 2594-2595, 1996.
Woods et al., “Thiazole Analogues of the NSAID Indomethacin as Selective COX-2 Inhibitors”,Bioorganic&Medicinal Chemistry Letters, vol. 11, pp. 1325-1328, 2001.
Jacobs, R. T. et al., “Substituted 3-(Phenylmethyl)-1H-indole-5-carboxamides and 1-(Phenylmethyl)indole-6-carboxamides as Potent, Selective, Orally Active Antagonists of the Peptidoleukotrienes”, J. Med. Chem., vol. 36, No. 3, pp. 394-409 (1993).

Affiliated with

Also associated with

Rating

Bicyclic heterocycles useful as serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic heterocycles useful as serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic heterocycles useful as serine protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4005853